Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

The multicenter Phase 1 study is currently enrolling and evaluating IO-202 as monotherapy and in combination with an anti-PD-1 for the treatment of solid tumors

Excerpt from the Press Release:

PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced that it will present a Trial in Progress poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held in Boston and virtually from November 8 –12, 2022.

The poster presentation will highlight the trial design, dosing regimen, and study protocol for the company’s ongoing Phase 1 clinical trial of IO-202, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with advanced solid tumors (NCT05309187).

“Our Phase 1 study of IO-202 supports a differentiated myeloid checkpoint inhibitor with best-in-class potential to provide benefit for patients with solid tumors,” said Paul Woodard, M.D., chief medical officer of Immune-Onc. “IO-202 blocks the LILRB4 pathway – specifically, interaction with its multiple ligands including apolipoprotein E and fibronectin – enabling the potential to reactivate or enhance anti-tumor T cell immune responses in patients with solid tumors.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release